Per-Lot COA Is Becoming Table Stakes — The Supplier Shakeout
The market for research chemicals has reached an inflection point where per-lot Certificates of Analysis (COAs) are no longer a differentiator but a baseline expectation. Suppliers that fail to provide them face regulatory consequences and rapid customer attrition.
For years, the industry operated on a trust-me model: a supplier posted a single representative COA, often months or years old, and buyers accepted it. That era is ending. The shift is driven by heightened enforcement from the Food and Drug Administration (FDA) and a buyer base burned by adulterated or mislabeled products. The result is a supplier shakeout that will leave only those willing to invest in batch-level documentation.
The Regulatory Hammer Is Falling
The FDA’s Center for Drug Evaluation and Research (CDER) has issued warning letters to research chemical suppliers with increasing frequency. A common thread is the absence of per-lot COAs. In a September 2023 warning letter to a major peptide supplier, the agency cited 21 CFR 211.84(d)(2), which requires that “each lot of a component” be tested for identity, strength, quality, and purity. The supplier had relied on a single COA from its overseas manufacturer without verifying it matched the specific lot shipped.
The FDA’s position is unambiguous: a COA must be tied to a specific lot, and the supplier must have conducted identity testing on that lot. The Federal Register notice of August 2022 (87 FR 50989) clarified that for components not subject to monograph standards, the supplier must establish “appropriate” specifications and test methods. Per-lot documentation is the only way to demonstrate compliance.
This is not a theoretical risk. In the first half of 2024 alone, the FDA issued four warning letters to research chemical distributors where the absence of per-lot COAs was a primary citation. One supplier operating out of a Nevada warehouse had its products seized under 21 U.S.C. 334 after FDA investigators found that its “sterile” water for injection had no batch-level endotoxin testing records. The supplier had been posting a single COA from a 2021 production run.
Buyers Are Voting With Their Wallets
Regulatory pressure is mirrored by market demand. Research institutions, contract labs, and independent chemists now require per-lot COAs as a condition of purchase. The reason is reproducibility. A 2023 survey by the American Society for Testing and Materials (ASTM) found that 78% of research labs had experienced at least one experiment failure attributable to an unverified reagent lot. When a COA is not lot-specific, the buyer cannot confirm the material in hand matches the claimed specifications.
This has created a bifurcated market. On one side are suppliers that have invested in per-lot COA infrastructure. BAC Water Depot, for example, publishes a unique COA for every batch of its bacteriostatic water for injection, listing the specific lot number, USP <71> sterility test result, USP <85> bacterial endotoxins test result, and exact sodium chloride concentration (0.9% w/v). The COAs are timestamped and include the technician’s initials, allowing buyers to trace a specific bottle back to its production run.
On the other side are suppliers that continue to rely on generic documentation. These vendors are losing business rapidly. One peptide distributor that had been in operation for over a decade reported a 40% drop in orders in Q1 2024 after a buyer discovered its COAs were not lot-specific. The company has since announced a temporary halt to operations while implementing a new quality management system.
The Cost of Compliance Is a Barrier to Entry
Producing per-lot COAs is not cheap. It requires either an in-house analytical laboratory or a contract with a third-party testing facility. For a supplier handling 50 SKUs, per-lot testing can run $50,000 to $100,000 annually, depending on the tests required. USP <797> compliance for sterile products adds environmental monitoring, personnel testing, and media-fill runs.
This cost structure is driving consolidation. Small suppliers that cannot afford testing infrastructure are exiting the market or being acquired by larger players. The shakeout is particularly acute in the peptide and diluent segments, where purity and sterility are non-negotiable.
Alpha Amino USA, a domestic peptide supplier, has adopted a different approach. Rather than publishing per-lot COAs for every product, the company provides a comprehensive quality dossier for each batch, including HPLC purity analysis, mass spectrometry confirmation, and residual solvent testing. Each batch is assigned a unique identifier, and documentation is available on request. This model works because the company controls its own synthesis and purification, maintaining batch-level traceability without the overhead of a separate testing lab.
The contrast with overseas suppliers is stark. A 2022 FDA import alert (89-08) specifically targeted peptide suppliers from China shipping products with no COAs at all. The alert allowed for detention without physical examination of any peptide product from those firms. The message was clear: if you cannot document your product, it will not enter the U.S. market.
The Future Is Batch-Level Transparency
The trend toward per-lot COAs is being codified into industry standards. ASTM’s E3207-22 standard for “Batch Identity Testing of Research Chemicals” explicitly requires that “each batch shall have a unique certificate of analysis that includes the batch identifier, the date of analysis, and the results of all applicable tests.” The standard is voluntary but is rapidly becoming a de facto requirement for suppliers that want to sell to institutional buyers.
The FDA is also moving toward mandatory batch-level documentation for all drug components, including those used in research. The proposed rule on “Current Good Manufacturing Practice for Active Pharmaceutical Ingredients” (81 FR 76698) would require that each batch of an API be accompanied by a COA including the batch number, date of manufacture, and results of all tests. While the rule is not yet final, its direction is clear.
For suppliers, the calculus is straightforward. Per-lot COAs are table stakes. Those that cannot provide them will be regulated out of existence or starved of customers. Those that can will have a durable competitive advantage. The shakeout is already underway, and the winners will be the ones that treat documentation not as a burden but as a core part of their product.